Skip to main content
Clinical Trials/NCT03999216
NCT03999216WithdrawnPhase 4

Creating a Platform for Point-of-Care Pragmatic Clinical Trials: Comparing Diuretic Strategies in Heart Failure

Stanford University1 site in 1 countryStarted: July 2023Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Withdrawn
Locations
1
Primary Endpoint
Hospital length of stay

Study Overview

Brief Summary

We will conduct a pragmatic randomized trial comparing whether using a combination of two types of diuretics (loop + thiazide) compared with using a single diuretic (loop only) will result in shorter hospital stays for patients hospitalized with heart failure.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Any adult (age ≥18 years) admitted to the Heart Failure Service at Stanford Health Care with an indication for treatment with a diuretic.

Exclusion Criteria

  • admission to the intensive care unit or cardiac care units
  • maintenance dialysis on admission
  • any mechanical circulatory support on admission
  • history of heart transplant
  • allergy / intolerance to loop or thiazide diuretics
  • admission serum sodium < 125 meq/L (from EPIC)
  • admission serum potassium < 3.0 meq/L (from EPIC)

Arms & Interventions

Loop only

Active Comparator

Participants will receive a loop diuretic for up to the first 72 hours of hospitalization. The specific drug, dose and route are left to the treating providers.

Intervention: Loop Diuretics vs. loop + thiazide diuretics (Drug)

Loop + Thiazide

Active Comparator

Participants will receive a loop+thiazide diuretic for up to the first 72 hours of hospitalization. The specific drugs, doses and routes are left to the treating providers.

Intervention: Loop Diuretics vs. loop + thiazide diuretics (Drug)

Outcomes

Primary Outcomes

Hospital length of stay

Time Frame: During hospitalization up to 90 days

Secondary Outcomes

  • Composite of all-cause rehospitalizations, emergency department visits, or death in the 30 days after hospital discharge.(30 days)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Tara I-Hsin Chang

Associate Professor of Medicine (Nephrology)

Stanford University

Study Sites (1)

Loading locations...

Similar Trials